{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:35:14Z","timestamp":1793082914595,"version":"4.5.0"},"reference-count":70,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,5,11]],"date-time":"2026-05-11T00:00:00Z","timestamp":1778457600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10 OD034259"],"award-info":[{"award-number":["S10 OD034259"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["S10 OD025234"],"award-info":[{"award-number":["S10 OD025234"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005189","name":"Blood Cancer United","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005189","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R61 CA287026"],"award-info":[{"award-number":["R61 CA287026"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Institutes of Health National Cancer Institute","doi-asserted-by":"publisher","award":["R01CA288855"],"award-info":[{"award-number":["R01CA288855"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100011713","name":"Worldwide Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100011713","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018866","name":"Paula and Rodger Riney Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018866","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100022084","name":"Peter MacCallum Cancer Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022084","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016058","name":"Lymph&Co Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016058","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021839","name":"Snowdome Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100021839","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018675","name":"The Kids' Cancer Project","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018675","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cell Reports"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.celrep.2026.117464","type":"journal-article","created":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T16:37:18Z","timestamp":1780418238000},"page":"117464","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["An orally active dual CBP\/p300 degrader targets core dependencies of multiple myeloma"],"prefix":"10.1016","volume":"45","author":[{"given":"Praveen Kumar","family":"Tiwari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bomin","family":"Ku","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Drew A.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Rizvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel","family":"Ojeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Duffy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonie","family":"Cluse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Devlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nenad","family":"Bartonicek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olga","family":"Motorna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann-Sophie","family":"Koglin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Karakyriakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaitlyn","family":"Gagnon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramya S.","family":"Iyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Egan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pat","family":"Greninger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Benz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caroline","family":"Greco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julia","family":"Norton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amruth","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric F.","family":"Zaniewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soroush","family":"Hajizadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Morris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Genna","family":"Mullen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajinkya S.","family":"Kawale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sangwon","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sai Reddy","family":"Doda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghu","family":"Vannam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Zou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilhelm","family":"Haas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Abner","family":"Louissaint","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricky W.","family":"Johnstone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6142-7241","authenticated-orcid":false,"given":"Christopher J.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.celrep.2026.117464_bib1","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.cell.2018.04.033","article-title":"Time-Resolved Analysis Reveals Rapid Dynamics and Broad Scope of the CBP\/p300 Acetylome","volume":"174","author":"Weinert","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117464_bib2","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1038\/nature24028","article-title":"Discovery of a selective catalytic p300\/CBP inhibitor that targets lineage-specific tumours","volume":"550","author":"Lasko","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117464_bib3","doi-asserted-by":"crossref","first-page":"1324","DOI":"10.1021\/acsmedchemlett.0c00155","article-title":"Discovery of CPI-1612: A Potent, Selective, and Orally Bioavailable EP300\/CBP Histone Acetyltransferase Inhibitor","volume":"11","author":"Wilson","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.celrep.2026.117464_bib4","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0262378","article-title":"CREBBP\/EP300 acetyltransferase inhibition disrupts FOXA1-bound enhancers to inhibit the proliferation of ER+ breast cancer cells","volume":"17","author":"Bommi-Reddy","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.celrep.2026.117464_bib5","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1016\/j.molcel.2021.04.015","article-title":"Targeting histone acetylation dynamics and oncogenic transcription by catalytic P300\/CBP inhibition","volume":"81","author":"Hogg","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.celrep.2026.117464_bib6","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1158\/1538-7445.AM2024-1691","article-title":"Abstract 1691: p300 catalytic inhibition selectively targets IRF4 oncogenic activity in multiple myeloma","volume":"84","author":"McKeown","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117464_bib7","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1182\/blood-2024-199779","article-title":"Tolerability and Clinical Activity of Novel First-in-Class Oral Agent, Inobrodib (CCS1477), in Combination with Pomalidomide and Dexamethasone in Relapsed\/Refractory Multiple Myeloma","volume":"144","author":"Searle","year":"2024","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2026.117464_bib8","doi-asserted-by":"crossref","first-page":"TPS3171","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS3171","article-title":"A phase 1, first-in-human, open-label study evaluating the safety, tolerability, pharmacokinetics, and efficacy of TT125-802 in patients with advanced solid tumors","volume":"42","author":"Boni","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.celrep.2026.117464_bib9","doi-asserted-by":"crossref","first-page":"6920","DOI":"10.1158\/1538-7445.AM2025-6920","article-title":"Abstract 6920: Targeting the AR co-activator CBP\/p300 in metastatic castration-resistant prostate cancer (mCRPC)","volume":"85","author":"Dutta","year":"2025","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117464_bib10","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s43018-023-00550-x","article-title":"Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias","volume":"4","author":"de Matos Simoes","year":"2023","journal-title":"Nat. Cancer"},{"key":"10.1016\/j.celrep.2026.117464_bib11","doi-asserted-by":"crossref","first-page":"1722","DOI":"10.1016\/j.celrep.2018.07.041","article-title":"Enhancer Activity Requires CBP\/P300 Bromodomain-Dependent Histone H3K27 Acetylation","volume":"24","author":"Raisner","year":"2018","journal-title":"Cell Rep."},{"key":"10.1016\/j.celrep.2026.117464_bib12","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.chembiol.2020.12.004","article-title":"Targeted degradation of the enhancer lysine acetyltransferases CBP and p300","volume":"28","author":"Vannam","year":"2021","journal-title":"Cell Chem. Biol."},{"key":"10.1016\/j.celrep.2026.117464_bib13","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1158\/2159-8290.CD-21-0385","article-title":"EP300 selectively controls the enhancer landscape of MYCN-amplified neuroblastoma","volume":"12","author":"Durbin","year":"2021","journal-title":"Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117464_bib14","doi-asserted-by":"crossref","first-page":"8178","DOI":"10.1021\/acs.jmedchem.3c00492","article-title":"Discovery of Exceptionally Potent, Selective, and Efficacious PROTAC Degraders of CBP and p300 Proteins","volume":"66","author":"Thomas","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117464_bib15","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1021\/acsmedchemlett.3c00490","article-title":"Discovery and Characterization of Active CBP\/EP300 Degraders Targeting the HAT Domain","volume":"15","author":"Cheng-S\u00e1nchez","year":"2024","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.celrep.2026.117464_bib16","doi-asserted-by":"crossref","first-page":"3094","DOI":"10.1021\/jacsau.4c00442","article-title":"Paralogue-Selective Degradation of the Lysine Acetyltransferase EP300","volume":"4","author":"Chen","year":"2024","journal-title":"JACS Au"},{"key":"10.1016\/j.celrep.2026.117464_bib17","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1021\/acs.jmedchem.3c01468","article-title":"Discovery of Novel PROTAC Degraders of p300\/CBP as Potential Therapeutics for Hepatocellular Carcinoma","volume":"67","author":"Chang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117464_bib18","doi-asserted-by":"crossref","first-page":"5275","DOI":"10.1021\/acs.jmedchem.3c02124","article-title":"Discovery of CBPD-268 as an Exceptionally Potent and Orally Efficacious CBP\/p300 PROTAC Degrader Capable of Achieving Tumor Regression","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117464_bib19","doi-asserted-by":"crossref","first-page":"5351","DOI":"10.1021\/acs.jmedchem.3c01789","article-title":"Discovery of CBPD-409 as a Highly Potent, Selective, and Orally Efficacious CBP\/p300 PROTAC Degrader for the Treatment of Advanced","volume":"67","author":"Chen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117464_bib20","doi-asserted-by":"crossref","first-page":"6952","DOI":"10.1021\/acs.jmedchem.3c02195","article-title":"Discovery of Highly Potent and Efficient CBP\/p300 Degraders with Strong In Vivo Antitumor Activity","volume":"67","author":"Hu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117464_bib21","doi-asserted-by":"crossref","first-page":"9194","DOI":"10.1021\/acs.jmedchem.4c00335","article-title":"Discovery of a Promising CBP\/p300 Degrader XYD129 for the Treatment of Acute Myeloid Leukemia","volume":"67","author":"Wu","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117464_bib22","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1021\/jacsau.4c00292","article-title":"Structure-Based Design of CBP\/EP300 Degraders: When Cooperativity Overcomes Affinity","volume":"4","author":"Cheng-S\u00e1nchez","year":"2024","journal-title":"JACS Au"},{"key":"10.1016\/j.celrep.2026.117464_bib23","doi-asserted-by":"crossref","first-page":"17290","DOI":"10.1021\/acs.jmedchem.4c01100","article-title":"Discovery of a Highly Potent PROTAC Degrader of p300\/CBP Proteins for the Treatment of Enzalutamide-Resistant Prostate Cancer","volume":"67","author":"Ma","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117464_bib24","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107427","article-title":"Design, synthesis and biological evaluation of new RNF126-based p300\/CBP degraders","volume":"148","author":"Lei","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.celrep.2026.117464_bib25","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature11005","article-title":"Systematic identification of genomic markers of drug sensitivity in cancer cells","volume":"483","author":"Garnett","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.celrep.2026.117464_bib26","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1016\/j.cell.2016.06.017","article-title":"A Landscape of Pharmacogenomic Interactions in Cancer","volume":"166","author":"Iorio","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.celrep.2026.117464_bib27","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/nchembio.1337","article-title":"Metrics other than potency reveal systematic variation in responses to cancer drugs","volume":"9","author":"Fallahi-Sichani","year":"2013","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.celrep.2026.117464_bib28","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1016\/j.ccell.2023.11.001","article-title":"Therapeutic targeting of EP300\/CBP by bromodomain inhibition in hematologic malignancies","volume":"41","author":"Nicosia","year":"2023","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117464_bib29","doi-asserted-by":"crossref","first-page":"2468","DOI":"10.1038\/s41588-025-02336-6","article-title":"Targeting histone H2B acetylated enhanceosomes via p300\/CBP degradation in prostate cancer","volume":"57","author":"Luo","year":"2025","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2026.117464_bib30","doi-asserted-by":"crossref","first-page":"9162","DOI":"10.1021\/acs.jmedchem.7b00796","article-title":"GNE-781, A Highly Advanced Potent and Selective Bromodomain Inhibitor of Cyclic Adenosine Monophosphate Response Element Binding Protein, Binding Protein (CBP)","volume":"60","author":"Romero","year":"2017","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.celrep.2026.117464_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2024.129676","article-title":"Exploration of bromodomain ligand-linker conjugation sites for efficient CBP\/p300 heterobifunctional degrader activity","volume":"102","author":"Kumar Tiwari","year":"2024","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.celrep.2026.117464_bib32","doi-asserted-by":"crossref","first-page":"26663","DOI":"10.1002\/anie.202108848","article-title":"Phenyl-Glutarimides: Alternative Cereblon Binders for the Design of PROTACs","volume":"60","author":"Min","year":"2021","journal-title":"Angewandte Chemie Int Ed."},{"key":"10.1016\/j.celrep.2026.117464_bib33","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1021\/acsmedchemlett.2c00436","article-title":"Phenyl Dihydrouracil: An Alternative Cereblon Binder for PROTAC Design","volume":"14","author":"Jarusiewicz","year":"2023","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.celrep.2026.117464_bib34","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1158\/1538-7445.AM2021-43","article-title":"Abstract 43: Discovery of ARV-110, a first in class androgen receptor degrading PROTAC for the treatment of men with metastatic castration resistant prostate cancer","volume":"81","author":"Snyder","year":"2021","journal-title":"Cancer Res."},{"key":"10.1016\/j.celrep.2026.117464_bib35","article-title":"Isoindolinone and indazole compounds for the degradation of EGFR","author":"Nasveschuk","year":"2021","journal-title":"Patent WO2021127561A1"},{"key":"10.1016\/j.celrep.2026.117464_bib36","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.ccell.2019.10.002","article-title":"A Potent and Selective Small-Molecule Degrader of STAT3 Achieves Complete Tumor Regression In Vivo","volume":"36","author":"Bai","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.celrep.2026.117464_bib37","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1038\/s41557-023-01379-8","article-title":"Proteolysis-targeting chimeras with reduced off-targets","volume":"16","author":"Nguyen","year":"2024","journal-title":"Nat. Chem."},{"key":"10.1016\/j.celrep.2026.117464_bib38","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41588-023-01348-4","article-title":"Acetylation of histone H2B marks active enhancers and predicts CBP\/p300 target genes","volume":"55","author":"Narita","year":"2023","journal-title":"Nat. Genet."},{"key":"10.1016\/j.celrep.2026.117464_bib39","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1158\/2643-3230.BCD-23-0062","article-title":"Transcriptional heterogeneity overcomes super-enhancer disrupting drug combinations in multiple myeloma","volume":"5","author":"Welsh","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117464_bib40","doi-asserted-by":"crossref","first-page":"2166","DOI":"10.1016\/j.molcel.2021.03.008","article-title":"Enhancers are activated by p300\/CBP activity-dependent PIC assembly, RNAPII recruitment, and pause release","volume":"81","author":"Narita","year":"2021","journal-title":"Mol. Cell"},{"key":"10.1016\/j.celrep.2026.117464_bib41","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.1128\/MCB.25.9.3575-3582.2005","article-title":"Myocyte Enhancer Factor 2 Acetylation by p300 Enhances Its DNA Binding Activity, Transcriptional Activity, and Myogenic Differentiation","volume":"25","author":"Ma","year":"2005","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.celrep.2026.117464_bib42","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1128\/MCB.17.2.1010","article-title":"Molecular Mechanisms of Myogenic Coactivation by p300: Direct Interaction with the Activation Domain of MyoD and with the MADS Box of MEF2C","volume":"17","author":"Sartorelli","year":"1997","journal-title":"Mol. Cell Biol."},{"key":"10.1016\/j.celrep.2026.117464_bib43","doi-asserted-by":"crossref","first-page":"4464","DOI":"10.1093\/nar\/gkr030","article-title":"Structure of p300 bound to MEF2 on DNA reveals a mechanism of enhanceosome assembly","volume":"39","author":"He","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2026.117464_bib44","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1182\/bloodadvances.2023009772","article-title":"MAF functions as a pioneer transcription factor that initiates and sustains myelomagenesis","volume":"7","author":"Katsarou","year":"2023","journal-title":"Blood Adv."},{"key":"10.1016\/j.celrep.2026.117464_bib45","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1002\/ajh.27419","article-title":"Still high risk? A review of translocation t(14;16) in multiple myeloma","volume":"99","author":"Mian","year":"2024","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.celrep.2026.117464_bib46","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1158\/2643-3230.BCD-25-0048","article-title":"ID2 Suppresses Multiple Myeloma Cell Proliferation by Repressing the Activity of the Transcription Factor TCF3","volume":"7","author":"Fulciniti","year":"2026","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.celrep.2026.117464_bib47","doi-asserted-by":"crossref","first-page":"4","DOI":"10.30802\/AALAS-JAALAS-20-000020","article-title":"Reference Values for Hematology, Plasma Biochemistry, Bone Marrow Cytology and Bone Histology of NOD .Cg-Prkdc scid Il2rg tm1Wjl\/SzJ Immunodeficient Mice","volume":"60","author":"Layssol-Lamour","year":"2021","journal-title":"J. Am. Assoc. Lab. Anim. Sci."},{"key":"10.1016\/j.celrep.2026.117464_bib48","doi-asserted-by":"crossref","DOI":"10.1172\/JCI153514","article-title":"Degradation of GSPT1 causes TP53-independent cell death in leukemia while sparing normal hematopoietic stem cells","volume":"132","author":"Sellar","year":"2022","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.celrep.2026.117464_bib49","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1021\/cr500452k","article-title":"Protein Lysine Acetylation by p300\/CBP","volume":"115","author":"Dancy","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.celrep.2026.117464_bib50","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1038\/s41589-023-01320-7","article-title":"Acetyl-CoA biosynthesis drives resistance to histone acetyltransferase inhibition","volume":"19","author":"Bishop","year":"2023","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.celrep.2026.117464_bib51","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.1182\/blood-2005-03-1173","article-title":"Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma","volume":"106","author":"Lonial","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.celrep.2026.117464_bib52","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1038\/nmeth.4435","article-title":"Thiol-linked alkylation of RNA to assess expression dynamics","volume":"14","author":"Herzog","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.celrep.2026.117464_bib53","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1186\/s13059-014-0550-8","article-title":"Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2","volume":"15","author":"Love","year":"2014","journal-title":"Genome Biol."},{"key":"10.1016\/j.celrep.2026.117464_bib54","doi-asserted-by":"crossref","first-page":"W90","DOI":"10.1093\/nar\/gkw377","article-title":"Enrichr: a comprehensive gene set enrichment analysis web server 2016 update","volume":"44","author":"Kuleshov","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2026.117464_bib55","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1038\/nmeth.1923","article-title":"Fast gapped-read alignment with Bowtie 2","volume":"9","author":"Langmead","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.celrep.2026.117464_bib56","doi-asserted-by":"crossref","DOI":"10.1186\/gb-2008-9-9-r137","article-title":"Model-based analysis of ChIP-Seq (MACS)","volume":"9","author":"Zhang","year":"2008","journal-title":"Genome Biol."},{"key":"10.1016\/j.celrep.2026.117464_bib57","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-17204-5","article-title":"QuPath: Open source software for digital pathology image analysis","volume":"7","author":"Bankhead","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.celrep.2026.117464_bib58","first-page":"587","article-title":"SynergyFinder Plus: Toward Better Interpretation and Annotation of Drug Combination Screening Datasets. Genom","volume":"20","author":"Zheng","year":"2022","journal-title":"Proteom. Bioinform."},{"key":"10.1016\/j.celrep.2026.117464_bib59","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nmeth.4401","article-title":"chromVAR: inferring transcription-factor-associated accessibility from single-cell epigenomic data","volume":"14","author":"Schep","year":"2017","journal-title":"Nat. Methods"},{"key":"10.1016\/j.celrep.2026.117464_bib60","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/nmeth1019","article-title":"Target-decoy search strategy for increased confidence in large-scale protein identifications by mass spectrometry","volume":"4","author":"Elias","year":"2007","journal-title":"Nat. Methods"},{"key":"10.1016\/j.celrep.2026.117464_bib61","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1186\/s12859-019-2849-7","article-title":"Quantification of experimentally induced nucleotide conversions in high-throughput sequencing datasets","volume":"20","author":"Neumann","year":"2019","journal-title":"BMC Bioinform"},{"key":"10.1016\/j.celrep.2026.117464_bib62","article-title":"Fast gene set enrichment analysis","author":"Korotkevich","year":"2021","journal-title":"bioRxiv"},{"key":"10.1016\/j.celrep.2026.117464_bib63","doi-asserted-by":"crossref","first-page":"10","DOI":"10.14806\/ej.17.1.200","article-title":"Cutadapt removes adapter sequences from high-throughput sequencing reads","volume":"17","author":"Martin","year":"2011","journal-title":"EMBnet J."},{"key":"10.1016\/j.celrep.2026.117464_bib64","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1093\/bioinformatics\/btq033","article-title":"BEDTools: a flexible suite of utilities for comparing genomic features","volume":"26","author":"Quinlan","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.celrep.2026.117464_bib65","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1093\/bioinformatics\/btt656","article-title":"featureCounts: an efficient general purpose program for assigning sequence reads to genomic features","volume":"30","author":"Liao","year":"2014","journal-title":"Bioinformatics"},{"key":"10.1016\/j.celrep.2026.117464_bib66","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1093\/bioinformatics\/btp616","article-title":"edgeR: a Bioconductor package for differential expression analysis of digital gene expression data","volume":"26","author":"Robinson","year":"2010","journal-title":"Bioinformatics"},{"key":"10.1016\/j.celrep.2026.117464_bib67","doi-asserted-by":"crossref","first-page":"W160","DOI":"10.1093\/nar\/gkw257","article-title":"deepTools2: a next generation web server for deep-sequencing data analysis","volume":"44","author":"Ram\u00edrez","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2026.117464_bib68","doi-asserted-by":"crossref","first-page":"D91","DOI":"10.1093\/nar\/gkh012","article-title":"JASPAR: an open-access database for eukaryotic transcription factor binding profiles","volume":"32","author":"Sandelin","year":"2004","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.celrep.2026.117464_bib69","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1021\/acsmedchemlett.1c00368","article-title":"Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands","volume":"12","author":"Bricelj","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.celrep.2026.117464_bib70","article-title":"Tyrosine kinase 2 (tyk2) degradation compounds and methods of use","author":"Liu","year":"2022","journal-title":"Patent WO2022100710A1"}],"container-title":["Cell Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726005425?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211124726005425?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T06:01:29Z","timestamp":1793080889000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211124726005425"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":70,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S2211124726005425"],"URL":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117464","relation":{},"ISSN":["2211-1247"],"issn-type":[{"value":"2211-1247","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"An orally active dual CBP\/p300 degrader targets core dependencies of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cell Reports","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.celrep.2026.117464","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117464"}}